Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Disc Medicine, Inc.

NASDAQ: IRON · Life Sciences · 6 alerts · CIK 1816736

Disc Medicine, Inc. stories on ALFA USA NewsRead the news →
Share price
$76.59Close, Nov 16
Market cap
$3.49B
Shares outstanding
45.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Disc Medicine, Inc. filings on SEC EDGAR ↗

8:42 AM ET 10-Q
Financial Results

Disc Medicine Q3 2026 Results: Net Loss of $59.5M, Loss Narrows

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on hematologic diseases, reporting as a large accelerated filer with 45,540,842 shares of common stock outstanding as of October 29, 2026. The company continues to incur significant net losses, has no products approved for commercial sale, and anticipates the need for substantial additional funding to support its clinical development programs, including bitopertin.

Key figure
Net loss $59.5M
8:38 AM ET 8-K
Financial Results

Disc Medicine Financial Results

Disc Medicine reported Q3 2026 financial results and provided a corporate update, highlighting the successful Phase 3 APOLLO trial of bitopertin which met all primary and secondary endpoints. The company plans to resubmit its NDA for bitopertin by year-end 2026 and recently strengthened its balance sheet with a $486 million public offering in October, extending its cash runway into 2030.

“In our first pivotal trial readout as a company, APOLLO delivered strong and compelling evidence of the potential clinical benefit of bitopertin for patients with EPP. We look forward to engaging with regulators with the goal of bringing an important, innovative medicine to this community as efficiently as possible.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer

“Alongside our anticipated end-of-Phase 2 FDA meeting for selcodebart in anemia of myelofibrosis in the fourth quarter and a strengthened balance sheet, we are well positioned to support the anticipated launch of bitopertin and advance two additional programs toward pivotal-stage development in 2027.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.